Skip to content
Bored Studies
RecruitingPhase 3

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

Eli Lilly and Company · NCT07613294

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 45–80 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
252
US sites recruiting
13
Study start
June 1, 2026
Record last updated
October 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a).

Participation will last about 120 weeks.

Being studied: Lepodisiran; Placebo

Conditions: Atherosclerosis; Cardiovascular Diseases; Lipoprotein(a)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have an Lp(a) ≥175 nmol/L
  • Have established cardiovascular (CV) disease or are at risk for a first CV event
  • Have angiographic evidence of coronary artery disease on screening CCTA
  • If taking lipid-lowering medications, inclusive of statins or prescription strength niacin and PCSK9 inhibitors, these should be stable for 8 weeks

Exclusion Criteria

  • Have had a major CV event less than 60 days before measurement of the Lp(a) level used for eligibility or uncontrolled high blood pressure at screening
  • Have moderate to severe renal dysfunction
  • Have severe heart failure
  • Have a history of coronary artery bypass graft surgery (CABG)
  • Have a planned coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft, or valvular intervention
  • Have had a procedure to remove lipoproteins from the blood or received therapy specifically targeting Lp(a)
  • Are unable to safely undergo CCTA due to medication intolerance, contrast allergies, or anatomical/technical factors

Recruiting US locations

  • Valley Clinical Trials, Inc.

    Northridge, CA 91325

    Site contact: 818-678-4900

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, CA 90502

    Site contact: 424-201-3000

  • Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care

    Fort Lauderdale, FL 33312

    Site contact: 954-963-7100

  • Jacksonville Center for Clinical Research

    Jacksonville, FL 32216

    Site contact: 904-730-0101

  • Merritt Island Medical Research, LLC

    Merritt Island, FL 32952

    Site contact: David Kirk

  • Inpatient Research Clinic

    Miami Lakes, FL 33014

    Site contact: 786-502-4303

  • Clinical Site Partners, LLC dba Flourish Research

    Winter Park, FL 32789

    Site contact: 407-740-8078

  • Profound Research LLC

    Farmington Hills, MI 48334

    Site contact: 947-254-1920

  • Vector Clinical Trials

    Las Vegas, NV 89128

    Site contact: 702-750-000

  • Heart and Vascular Research at WellSpan Health

    York, PA 17403

    Site contact: 717-851-2441

  • Intermountain Medical Center

    Murray, UT 84107

    Site contact: 801-507-4707

  • Carilion Clinic

    Roanoke, VA 24014

    Site contact: Lana Wahid

  • Eastside Research Associates

    Redmond, WA 98052

    Site contact: 425-869-6828

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All heart & blood pressure studies in California →
A Study to See if Lepodisiran Can Reduce Plaque in Coronary… (NCT07613294) | Bored Studies